Cargando…

Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination

We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Nuri, Jeong, Seri, Lee, Su Kyung, Cho, Eun-Jung, Hyun, Jungwon, Park, Min-Jeong, Song, Wonkeun, Kim, Hyun Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321317/
https://www.ncbi.nlm.nih.gov/pubmed/35891307
http://dx.doi.org/10.3390/vaccines10071143
_version_ 1784756015348056064
author Lee, Nuri
Jeong, Seri
Lee, Su Kyung
Cho, Eun-Jung
Hyun, Jungwon
Park, Min-Jeong
Song, Wonkeun
Kim, Hyun Soo
author_facet Lee, Nuri
Jeong, Seri
Lee, Su Kyung
Cho, Eun-Jung
Hyun, Jungwon
Park, Min-Jeong
Song, Wonkeun
Kim, Hyun Soo
author_sort Lee, Nuri
collection PubMed
description We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 infection during the 4-month study period, with infection occurring 7–62 days before the second blood draw. Total antibody titers against the anti-spike (anti-S) and anti-nucleocapsid (anti-N) proteins of SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S and Elecsys Anti-SARS-CoV-2 assays (Roche), respectively. The median anti-S antibody titer in the non-infected groups at 4 months after the third dose was significantly decreased compared to that at 1 month after the third dose (from 17,777 to 3673 U/mL, p < 0.001). The infected group showed higher median anti-S antibody titers at 4 months (19,539 U/mL) than the non-infected group (3673 U/mL). The median anti-N antibody titer in the infected group at 4 months after the third dose was a 5.07 cut-off index (79.3% positivity). Anti-N antibody titers in the infected group were correlated with the number of days after SARS-CoV-2 infection. These data provide useful information for determining quarantine strategies and fourth vaccination requirements.
format Online
Article
Text
id pubmed-9321317
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93213172022-07-27 Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination Lee, Nuri Jeong, Seri Lee, Su Kyung Cho, Eun-Jung Hyun, Jungwon Park, Min-Jeong Song, Wonkeun Kim, Hyun Soo Vaccines (Basel) Article We quantitatively analyzed SARS-CoV-2 antibody levels in patients after two doses of the ChAdOx1 nCoV-19 vaccine and the third BNT162b2 booster. We obtained 255 serum samples from 149 healthcare workers 1 and 4 months after the third dose. Of the 149 participants, 58 (38.9%) experienced COVID-19 infection during the 4-month study period, with infection occurring 7–62 days before the second blood draw. Total antibody titers against the anti-spike (anti-S) and anti-nucleocapsid (anti-N) proteins of SARS-CoV-2 were measured using Elecsys Anti-SARS-CoV-2 S and Elecsys Anti-SARS-CoV-2 assays (Roche), respectively. The median anti-S antibody titer in the non-infected groups at 4 months after the third dose was significantly decreased compared to that at 1 month after the third dose (from 17,777 to 3673 U/mL, p < 0.001). The infected group showed higher median anti-S antibody titers at 4 months (19,539 U/mL) than the non-infected group (3673 U/mL). The median anti-N antibody titer in the infected group at 4 months after the third dose was a 5.07 cut-off index (79.3% positivity). Anti-N antibody titers in the infected group were correlated with the number of days after SARS-CoV-2 infection. These data provide useful information for determining quarantine strategies and fourth vaccination requirements. MDPI 2022-07-18 /pmc/articles/PMC9321317/ /pubmed/35891307 http://dx.doi.org/10.3390/vaccines10071143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Nuri
Jeong, Seri
Lee, Su Kyung
Cho, Eun-Jung
Hyun, Jungwon
Park, Min-Jeong
Song, Wonkeun
Kim, Hyun Soo
Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title_full Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title_fullStr Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title_full_unstemmed Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title_short Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
title_sort quantitative analysis of anti-n and anti-s antibody titers of sars-cov-2 infection after the third dose of covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321317/
https://www.ncbi.nlm.nih.gov/pubmed/35891307
http://dx.doi.org/10.3390/vaccines10071143
work_keys_str_mv AT leenuri quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT jeongseri quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT leesukyung quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT choeunjung quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT hyunjungwon quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT parkminjeong quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT songwonkeun quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination
AT kimhyunsoo quantitativeanalysisofantinandantisantibodytitersofsarscov2infectionafterthethirddoseofcovid19vaccination